Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma

Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study

(2016) Amishi Y. Shah et al.   BJU INTERNATIONAL

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas

(2016) Julien Calderaro et al.   EUROPEAN UROLOGY

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study

(2016) Stéphane Lepretre et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression

(2015) Jacob S Lipkin et al.   CANCER BIOLOGY & THERAPY

Clinical outcome and prognostic factors in renal medullary carcinoma. A pooled analysis from 18 years of medical literature.

(2015) Roberto Iacovelli et al.   CUAJ-Canadian Urological Association Journal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal medullary carcinoma and sickle cell trait: A systematic review

(2015) Ofelia Alvarez et al.   PEDIATRIC BLOOD & CANCER

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution

(2015) Michal Kovac et al.   Nature Communications

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity

(2012) Amir A. Toor et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma

(2012) Nizar M. Tannir et al.   EUROPEAN UROLOGY

SMARCB1/INI1 inactivation in renal medullary carcinoma

(2012) Julien Calderaro et al.   HISTOPATHOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior

(2008) Jason X Cheng et al.   MODERN PATHOLOGY

High-Dose-Intensity MVAC for Advanced Renal Medullary Carcinoma: Report of Three Cases and Literature Review

(2008) W. Kimryn Rathmell et al.   UROLOGY